Leaders in Health Industry Join Forces to Address Mental Health and Substance Use
Disorder
Number of shares in the Public Float2: 221,867,522 as of date: 09/30/2021
Total number of shareholders of record: 106 as of date: 09/30/2021
Leaders in Health Industry Join Forces to Address Mental Health and Substance Use
Disorder
UNIVEC, Inc. and bioRemedies MD Align to Introduce products offering safe alternative to
pain, anxiety and sleep disorders
Baltimore, MD (October 28, 2021) – Dr. David Dalton, CEO of UNIVEC, Inc. (OTC Markets:(UNVC)
and Patrick Kelly, President of bioRemedies MD, LLC announced a breakthrough partnership to
offer safe adjunct therapies for pain, anxiety and sleep disorders in the behavioral health
setting.
Through a variety of proprietary formulated cannabinoid-based products developed by
bioRemedies MD, Univec, Inc. is prepared to begin using these products in clinical behavioral
health settings for out-patient treatment. bioRemedies MD specializes in Cannabinoid
complementary and integrative products that have been in research and development at the
University of Maryland Baltimore BioPark since 2016 after industrial hemp research was
legitimized.
bioRemedies MD develops scientifically formulated cannabinoid products using FDA and
Pharmaceutical processes, technology, and standards to ensure high quality, reproducible, and
targeted formulations unlike anything in the market today. Their proprietary nanotechnology
delivers cannabinoids efficiently and effectively, which is required for academic research and
healthcare target markets and allows our commercial products to compete on quality and cost.
Univec, Inc. (OTC Markets:(UNVC) is an organization with a mission to change the way
healthcare is delivered in America. Having recently announced the acquisition of several
community based out-patient mental health centers to treat behavioral health. bioRemedies
MD compliments Univec, Inc. (UNVC) principles--treating the patient as whole and applying
“Total Wraparound” for patient, family and caregiver support.
Patrick Kelly, President of bioRemedies MD, LLC, remarked, “the time is now to bring these
products to the community weary from substance use disorders and barriers to mental health
treatment. This partnership with Univec, Inc. meets people where they are to help those
suffering from pain, opioid misuse, anxiety and sleep disorders.
Univec, Inc. will make private label and bioRemedies MD products available through several
distribution channels, including the recently acquired mental health centers. For additional
information about access to treatment
Univec Inc (UNVC)
